Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael Rabbia
Michael Rabbia
Genentech
Disease
Medicine
Crenezumab
Tolerability
Psychiatry
4
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Disease Modification in Alzheimer’s Disease: Current Thinking:
2019
Therapeutic Innovation & Regulatory Science
Hong Liu-Seifert
Jennifer Schumi
Xiaopeng Miao
Ying Tian
Michael Rabbia
Scott W. Andersen
Steve Wilson
Wen Li
Richard Entsuah
Show All
Source
Cite
Save
Citations (5)
Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) (P4.1-002)
2019
Neurology
Kaycee M. Sink
Susanne Ostrowitzki
Laurie Millar
Francis Warren
Helen Lin
Jillian Smith
Andres Schneider
Reina N. Fuji
Angelica Quartino
Howard Mackey
Michael Rabbia
Susan Yule
Paulo Fontoura
Rachelle Doody
Show All
Source
Cite
Save
Citations (0)
A Phase 1b/2 Study of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update (P1.6-062)
2019
Neurology
Kathryn R. Wagner
Brenda L. Wong
Barry J. Byrne
C. Tian
Leslie K. Jacobsen
Giridhar Tirucherai
Michael Rabbia
Heidemarie Kletzl
Juergen Dukart
Rose Ong
Karl Yen
G. Sajeev
James Signorovitch
Susan Ward
Cliff Bechtold
Michelle L. Krishnan
Show All
Source
Cite
Save
Citations (4)
BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER’S DISEASE (CREAD)
2018
Alzheimers & Dementia
Helen Lin
Susanne Ostrowitzki
Kaycee M. Sink
Laurie Millar
Francis Warren
Jillian Smith
Andres Schneider
Reina N. Fuji
Angelica Quartino
Howard Mackey
Michael Rabbia
Susan Yule
Paulo Fontoura
Rachelle Doody
Show All
Source
Cite
Save
Citations (1)
1